Drug-controlled CAR T cells through the regulation of cell-cell interactions - PubMed
a day ago
- #DROP-CARs
- #CAR T cell therapy
- #cancer immunotherapy
- CAR T cell therapy faces challenges like on-target, off-tumor toxicities and cellular exhaustion due to chronic antigen exposure.
- DROP-CARs (venetoclax-controlled drug-regulated off-switch PPI-CARs) enable dose-dependent release of tumor-targeting scFv, reducing T cell binding to tumor cells.
- Proof of concept includes dual DROP-CARs controlled by different small molecules and logic-gated synthetic receptors for STAT3 signaling.
- DROP-CAR T cells show in vitro and in vivo functionality, indicating potential for clinical application.
- Intellectual property rights for the DROP mechanism are held by M.I., B.E.C., G.G.A., L.S., and colleagues.